NANOVIRICIDES NEW DL-01
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product for… Read more
Market Cap & Net Worth: NANOVIRICIDES NEW DL-01 (NV3P)
NANOVIRICIDES NEW DL-01 (F:NV3P) has a market capitalization of $19.81 Million (€19.30 Million) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #25947 globally and #2834 in its home market, demonstrating a 21.77% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NANOVIRICIDES NEW DL-01's stock price €0.90 by its total outstanding shares 21568429 (21.57 Million).
NANOVIRICIDES NEW DL-01 Market Cap History: 2016 to 2026
NANOVIRICIDES NEW DL-01's market capitalization history from 2016 to 2026. Data shows change from $30.86 Million to $19.81 Million (-4.51% CAGR).
NANOVIRICIDES NEW DL-01 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NANOVIRICIDES NEW DL-01's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of NV3P by Market Capitalization
Companies near NANOVIRICIDES NEW DL-01 in the global market cap rankings as of March 18, 2026.
Key companies related to NANOVIRICIDES NEW DL-01 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
NANOVIRICIDES NEW DL-01 Historical Marketcap From 2016 to 2026
Between 2016 and today, NANOVIRICIDES NEW DL-01's market cap moved from $30.86 Million to $ 19.81 Million, with a yearly change of -4.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €19.81 Million | +2.87% |
| 2025 | €19.26 Million | -39.58% |
| 2024 | €31.88 Million | +53.19% |
| 2023 | €20.81 Million | -11.86% |
| 2022 | €23.61 Million | -66.08% |
| 2021 | €69.61 Million | +176.03% |
| 2020 | €25.22 Million | -18.29% |
| 2016 | €30.86 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of NANOVIRICIDES NEW DL-01 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $19.81 Million USD |
| MoneyControl | $19.81 Million USD |
| MarketWatch | $19.81 Million USD |
| marketcap.company | $19.81 Million USD |
| Reuters | $19.81 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.